Singapore-headquartered surgical robotics firm Biobot Surgical has announced raising S$20 million (about $15.5 million) in its latest financing round anchored by Temasek-established firm ClavystBio.
The announcement confirms DealStreetAsia’s report in April that the company raised fresh funding from new investor ClavystBio and existing cornerstone shareholder ZIG Ventures Limited.
The company said on Monday that the fresh capital will be used to expand adoption of its Mona Lisa robotic platform for prostate cancer diagnosis and treatment, strengthen its clinical evidence base, and build commercial capabilities in key overseas markets.
Biobot said its Mona Lisa platform combines robotic needle guidance with MRI-ultrasound image fusion to support targeted prostate biopsies and focal ablation procedures.
The company said it has installed more than 80 systems worldwide and supported over 30,000 patients, with deployments across hospitals in Europe and the Asia-Pacific region.
Read Full Article At Source
